{"id":2830,"date":"2021-11-30T10:07:28","date_gmt":"2021-11-30T09:07:28","guid":{"rendered":"https:\/\/wp.idlbiotech.com\/?page_id=2830"},"modified":"2026-04-28T17:10:14","modified_gmt":"2026-04-28T15:10:14","slug":"arsstamma","status":"publish","type":"page","link":"https:\/\/idldiagnostics.com\/sv\/investerare\/foretagsstyrning\/arsstamma\/","title":{"rendered":"\u00c5rsst\u00e4mma"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”88f366a5-bf49-48d9-a338-ab22706b73e7″ global_colors_info=”{}”][et_pb_row _builder_version=”4.18.0″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||||false|false” custom_padding_tablet=”10px||||false|false” custom_padding_phone=”0px||||false|false” custom_padding_last_edited=”on|phone” global_colors_info=”{}”][dipi_breadcrumbs _builder_version=”4.16″ _module_preset=”default” max_width=”800px” global_colors_info=”{}”][\/dipi_breadcrumbs][et_pb_divider color=”#EEEEEE” _builder_version=”4.16″ _module_preset=”default” max_width=”800px” min_height=”1px” height=”20px” custom_margin=”||3px|||” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.27.4″ _module_preset=”8738c908-7375-4c6c-99a7-9f91f8a3c099″ header_font_size=”56px” max_width=”800px” custom_margin=”||17px|||” global_colors_info=”{}”]<\/p>\n

\u00c5rsst\u00e4mma<\/h6>\n

\u00c5rsst\u00e4mma<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” width=”100%” max_width=”100%” global_colors_info=”{}”]<\/p>\n

R\u00e4tt att delta vid \u00e5rsst\u00e4mman<\/h3>\n

Aktie\u00e4garnas r\u00e4tt att besluta om bolagets angel\u00e4genheter ut\u00f6vas genom bolagets h\u00f6gsta beslutande organ, \u00e5rsst\u00e4mman (\u00e5rsst\u00e4mma och extra bolagsst\u00e4mma).<\/p>\n

Aktie\u00e4gare som \u00f6nskar delta vid bolagets \u00e5rsst\u00e4mma ska vara inf\u00f6rd i aktieboken som f\u00f6rs av Euroclear Sweden senast fem vardagar f\u00f6re st\u00e4mman och anm\u00e4la sitt deltagande i \u00e5rsst\u00e4mman senast det datum som anges i kallelsen till st\u00e4mman. Aktie\u00e4gare kan n\u00e4rvara vid bolagsst\u00e4mman personligen eller genom ombud och f\u00e5r \u00e4ven bitr\u00e4das av h\u00f6gst tv\u00e5 personer. Hur aktie\u00e4gare registrerar sig f\u00f6r \u00e5rsst\u00e4mman anges n\u00e4rmare i kallelsen till st\u00e4mman. Aktie\u00e4gare har r\u00e4tt att r\u00f6sta f\u00f6r samtliga aktier som innehas av aktie\u00e4garen.<\/p>\n

Kallelse till bolagsst\u00e4mma ska publiceras i Post- och Inrikes Tidningar och p\u00e5 bolagets webbplats inom den tid som anges i aktiebolagslagen. Det ska \u00e4ven annonseras i Dagens Industri att kallelsen har utf\u00e4rdats.<\/p>\n

Aktie\u00e4gare som \u00f6nskar f\u00e5 ett \u00e4rende behandlat p\u00e5 \u00e5rsst\u00e4mman m\u00e5ste skicka en skriftlig beg\u00e4ran om detta till bolagets styrelse. Beg\u00e4ran b\u00f6r normalt inkomma till styrelsen senast sex veckor f\u00f6re \u00e5rsst\u00e4mman.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_accordion toggle_icon=”3||divi||400″ _builder_version=”4.27.6″ _module_preset=”default” global_colors_info=”{}” border_width_all=”0px” border_width_bottom=”1px”][et_pb_accordion_item title=”#1 – R\u00f6r ej” _builder_version=”4.17.4″ _module_preset=”default” custom_css_main_element=”Display:none;” global_colors_info=”{}” open=”off”][\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2026″ open=”on” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

All documents are in Swedish.<\/h5>\n

Kallelse till \u00e5rsst\u00e4mma 2026<\/a><\/p>\n

Bilaga 1 Valberedningens motiverade yttrande och information om styrelseledam\u00f6ter 2026<\/a><\/p>\n

Fullmaktsformul\u00e4r<\/a><\/p>\n

Postr\u00f6stningsformul\u00e4r<\/a><\/p>\n

Valberedningens f\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman 2026<\/a><\/p>\n

 <\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2025″ open=”off” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

All documents are in Swedish.<\/h5>\n

Kallelse till \u00e5rsst\u00e4mma 2025<\/a><\/p>\n

Bilaga 1 Valberedningens motiverade yttrande och information om styrelseledam\u00f6ter 2025<\/a><\/p>\n

Fullmaktsformul\u00e4r<\/a><\/p>\n

F\u00f6rslag om emissionsbemyndigande 2025<\/a><\/p>\n

F\u00f6rslag om \u00e4ndring av bolagsordning<\/span><\/a><\/p>\n

L\u00e4nk till onlineregistrering<\/a><\/p>\n

L\u00e4nk till digital brevr\u00f6stning<\/a><\/p>\n

Valberedningens f\u00f6rslag inf\u00f6r \u00e5rsst\u00e4mman 2025<\/a><\/p>\n

Protokoll fr\u00e5n \u00e5rsst\u00e4mma 2025<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2024″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

All documents are in Swedish.<\/h5>\n

Notice of Annual General Meeting 2024<\/a><\/p>\n

Appendix 1 The Nomination Committee’s reasoned statement and information on board members<\/a><\/p>\n

Authorization form<\/a><\/p>\n

Proposal for issue authorization in 2024<\/a><\/p>\n

Link to online registration<\/a><\/p>\n

Link to digital mail vote<\/a><\/p>\n

The nomination committee’s proposal for the 2023 annual general meeting<\/a><\/p>\n

<\/a>Minutes from the Annual General Meeting 2024<\/a><\/p>\n

 <\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2023″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

All documents are in Swedish.<\/h5>\n

Notice of Annual General Meeting 2023<\/a><\/p>\n

Appendix 1 The Nomination Committee’s reasoned statement and information on board members<\/a><\/p>\n

Authorization form<\/a><\/p>\n

Proposal for a directed issue of warrants<\/a><\/p>\n

Warrant terms<\/a><\/p>\n

Issuance authorization<\/a><\/p>\n

Link to online registration<\/a><\/p>\n

Link to digital mail vote<\/a><\/p>\n

The nomination committee’s proposal for the 2023 annual general meeting<\/a><\/p>\n

Minutes from the Annual General Meeting 2023<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2022″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

All documents are in Swedish.<\/h5>\n

Notice of Annual General Meeting 2022<\/a><\/p>\n

Issue authorization<\/a><\/p>\n

The Nomination Committee\u2019s proposal for the 2022 Annual General Meeting<\/a><\/p>\n

Proposal for new articles of association<\/a><\/p>\n

Minutes from the Annual General Meeting 2022 \u2013 With attachments<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2021″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

All documents are in Swedish.<\/h5>\n

Notice of annual general meeting of AroCell AB<\/a><\/p>\n

The Board\u2019s proposal \u2013 Authorization<\/a><\/p>\n

Nomination Committee\u2019s proposal to the Annual General Meeting 2021<\/a><\/p>\n

Proposal for new articles of association<\/a><\/p>\n

Minutes from the Annual General Meeting 2021<\/a><\/p>\n

\u2013Attachment 1<\/a><\/p>\n

\u2013Attachment 2<\/a><\/p>\n

\u2013Attachment 3<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2020″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

All documents are in Swedish.<\/h5>\n

Notice of annual general meeting of AroCell AB<\/a><\/p>\n

The Board\u2019s proposal \u2013 Authorization<\/a><\/p>\n

Nomination Committee\u2019s proposal to the Annual General Meeting 2020<\/a><\/p>\n

Information regarding the Annual General Meeting 2020<\/a><\/p>\n

Minutes from the Annual General Meeting 2020<\/a><\/p>\n

Presentation AroCell AB (publ) Annual General Meeting 2020<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2019″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

All documents are in Swedish.<\/h5>\n

Notice of annual general meeting of AroCell AB<\/a>
\u2013 Comment on the Nomination Committee\u2019s proposal for Board members (Swedish)<\/a><\/p>\n

Nomination Committee\u2019s proposal to the Annual General Meeting 2019<\/a><\/p>\n

The Board\u2019s proposal \u2013 Change<\/a><\/p>\n

The Board\u2019s proposal \u2013 Authorization<\/a><\/p>\n

The Board\u2019s proposal \u2013 Directed issue NR1<\/a>
\u2013 Agreement NR1<\/a>
\u2013 Appendix 1 NR1<\/a>
\u2013 Appendix 2 NR1<\/a><\/p>\n

Jon Eiken\u2019s proposal \u2013 Directed issue NR2<\/a>
\u2013 Agreement NR2<\/a>
\u2013 Appendix 1 NR2<\/a>
\u2013 Appendix 2 NR2<\/a><\/p>\n

Presentation AroCell AB (publ) Annual General Meeting 2019<\/a><\/p>\n

Minutes from the Annual General Meeting<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2018″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

Kallelse till \u00e5rsstamma 2018 AroCell AB (Publ)<\/a><\/p>\n

Presentation AroCells styrelse 2018<\/p>\n

Instruktion och arbetsordning f\u00f6r valberedningen i AroCell<\/p>\n

Presentation \u00e5rsst\u00e4mma 2018 AroCell AB (publ)<\/p>\n

2018-06-15 kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma<\/p>\n

Protokoll fr\u00e5n \u00e5rsst\u00e4mma<\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2017″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

Presentation \u00e5rsst\u00e4mman 2017 AroCell AB (publ)<\/a><\/p>\n

Beslut vid \u00e5rsst\u00e4mman i AroCell AB 2017 (Publ)<\/a><\/p>\n

Kallelse till \u00e5rsst\u00e4mma 2017 AroCell AB (Publ)<\/a><\/p>\n

Presentation AroCell AB styrelse 2017<\/a><\/p>\n

Styrelsens f\u00f6rslag till Personaloptionsprogram 2017-2020<\/a><\/p>\n

Optionsvillkor AroCell AB<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2016″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

Notice of Annual General Meeting 2016 (SWE)<\/a><\/p>\n

Proposal by the Board of Directors on authorization (SWE)<\/a><\/p>\n

Instructions for the Nomination Committee (SWE)<\/a><\/p>\n

AroCell-PR-160519-Report-AGM-Eng<\/a><\/p>\n

AroCell-PM-160519-Kommunik\u00e9\u200b (SWE)<\/a><\/p>\n

[\/et_pb_accordion_item][et_pb_accordion_item title=”\u00c5rsst\u00e4mma 2015″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}” open=”off”]<\/p>\n

The annual general meeting of AroCell AB (publ) was held on 3 June 2015. The following provides a summary of the resolutions passed. All resolutions were passed with the required majority.<\/h5>\n

4,627,983 (19.7 %) of the total of 23,460,960 shares were represented at the meeting.<\/p>\n

The meeting passed a resolution to adopt the presented income statement and balance sheet. The meeting also passed a resolution to allocate the company\u2019s loss in accordance with the Board of Directors\u2019 proposal in the annual accounts. It was further resolved that no dividend would be paid for the 2014 financial year.<\/p>\n

The general meeting passed a resolution regarding discharge from liability for members of the Board of Directors and the CEO.<\/p>\n

The general meeting passed a resolution that the Board of Directors shall comprise five ordinary members and to appoint one auditor without a deputy.<\/p>\n

The meeting passed a resolution that the board fee shall be SEK 150,000 for the chairman and SEK 50,000 for other board members. It was further resolved that the auditor\u2019s fee shall be based on an approved invoice.<\/p>\n

The general meeting passed a resolution to re-elect Erik Walld\u00e9n, H\u00e5kan Englund, Staffan Eriksson and Jan Mellberg, and to elect Carl Blomqvist as a new member of the Board. Erik Walld\u00e9n was appointed chairman of the Board of Directors.<\/p>\n

The meeting re-elected Bj\u00f6rn Ohlsson of Ernst & Young as auditor.<\/p>\n

All the above elections relate to the period until the next annual general meeting.<\/p>\n

The meeting passed a resolution to appoint a nominating committee ahead of the 2016 annual general meeting and adopted Instructions and rules of procedure for the nominating committee.<\/p>\n

The meeting passed a resolution to authorise the Board of Directors to decide to implement a new issue of shares or other financial instruments in accordance with the proposal in the notice convening the meeting. The resolution was passed unanimously.<\/p>\n

For further information:
Jan St\u00e5lemark, CEO
AroCell AB (publ)
Tel: +46 (0)18-50 30 20
E-mail: jan.stalemark@arocell.com<\/p>\n

AroCell AB (publ) in brief<\/strong>
AroCell AB (publ) is a Swedish company located in Uppsala. AroCell\u2019s technology is based on an innovative method for measuring how quickly cells divide in the body, which can provide a measure of how aggressive a cancer tumour is. This is done using a simple blood sample and a laboratory test. The test, TK 210 ELISA, provides clinically valuable information for assessing prognosis, monitoring the effectiveness of cancer treatment, and treatment optimisation. The test is also ideal for following up and checking for possible recurrence. AroCell is listed on the AktieTorget marketplace in Sweden and has around 1,650 shareholders.<\/p>\n

[\/et_pb_accordion_item][\/et_pb_accordion][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_module=”3466″ saved_tabs=”all” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_menu menu_id=”29″ disabled_on=”on|on|off” _builder_version=”4.18.0″ _module_preset=”default” background_color=”#F8F8F8″ global_colors_info=”{}”][\/et_pb_menu][et_pb_sidebar area=”et_pb_widget_area_2″ disabled_on=”off|off|on” _builder_version=”4.16″ _module_preset=”2efbbc8f-7ecb-4fe3-9956-d83a8a0e7a74″ background_color=”#F8F8F8″ global_colors_info=”{}”][\/et_pb_sidebar][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”4.9.4″ _module_preset=”default” custom_margin_tablet=”||||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|tablet” custom_padding_tablet=”||0px||false|false” custom_padding_phone=”” global_module=”2177″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.27.4″ _module_preset=”default” width=”90%” max_width=”2000px” global_colors_info=”{}”][et_pb_column type=”1_2″ module_class=”ds-vertical-align” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Om oss<\/h6>\n

Vi bist\u00e5r med kunskap till beslutsfattare<\/h3>\n

IDL Diagnostics \u00e4r ett svenskt diagnostikf\u00f6retag med visionen att f\u00f6rb\u00e4ttra \u00f6vervakningen av onkologiska och bakteriella sjukdomar. Vi har ett brett produktutbud av IVD-tester som levererar v\u00e4rdefull klinisk information f\u00f6r uppt\u00e4ckt av sjukdomar.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/idldiagnostics.com\/sv\/om-arocell\/” button_text=”L\u00e4s mer om oss” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2022\/10\/MG_7941-800.jpg” title_text=”MG_7941-600″ src_tablet=”” src_phone=”https:\/\/idldiagnostics.com\/sv\/wp-content\/uploads\/2023\/08\/MG_7941-600.jpg” src_last_edited=”on|phone” _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t
\n\t\t\t\t\t
\n